From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.
In the latest video of our Cells series, part of the GOBOLDLY™ campaign, we witness the destruction of a rogue cell that causes rheumatoid arthritis (RA), a disease that affects 1.3 million Americans.
RA is a painful and crippling autoimmune disease that is, simply put, the body’s own immune system attacking the joints. With this disease, normally beneficial immune cells, called B cells and T cells, go “rogue,” attacking joints and causing inflammation and pain.
Over the last decade, we’ve seen a number of advancements in treatments for RA, including a new first-in-class oral medicine offering greater convenience for patients. But researchers at America’s biopharmaceutical companies aren’t stopping there. They are working tirelessly to develop more weapons to combat and destroy these rogue cells, with the hope of one day giving patients the opportunity for a life free of pain.
Learn more about the fight against rheumatoid arthritis at GoBoldly.com and Innovation.org.
Robert Zirkelbach Robert Zirkelbach is Executive Vice President of Public Affairs at PhRMA. He joined PhRMA in 2014 after working for seven years representing the health insurance industry. He likes Saturday afternoon BBQs on his deck, traveling, trying new restaurants, and attempting to play golf. He’s an avid, somewhat obsessive, Iowa Hawkeye fan and is lucky to have a wife that loves watching college football on Saturday afternoons.
Topics: Rheumatoid Arthritis, GoBoldly
Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)